N-Power Medicine
N-Power Medicine is a fast-growing startup seeking a seasoned Technical Contract Recruiter to handle full-cycle recruiting for clinical, technical, and AI-driven roles in a remote, high-growth environment. The role involves developing recruiting strategies, engaging top talent, and building strong pipelines to support company scaling efforts.
Headquarters
Redwood City, California, United States
Company Size
51-200 employees
Founded
2021
N-Power Medicine operates an always-on clinical research system embedded in community oncology practices, turning routine care into research to accelerate and de-risk oncology drug development. Its offerings include the Kaleido Registry, prospective external control cohorts, and a Community Trial Accelerator that enable robust comparator groups, comprehensive pre‑screening, and signal-based site activation to improve enrollment and trial diversity. A human-in-the-loop AI platform, embedded virtual staff, and point-of-care EHR integration reduce clinician burden and surface eligible patients across a growing network of community oncologists. The company emphasizes security and quality (HIPAA, ISO 27001, ISO 9001) to deliver faster, more reliable development decisions for sponsors.
N-Power Medicine and AdventHealth Collaborate to Expand Access to Cancer Care and Research
Jan 8, 2026
N-Power Medicine Launches Industry’s First Prospective External Control Arm Platform to Dramatically Accelerate Oncology Drug Development and Reduce Reliance on Randomization
Aug 19, 2025
N-Power links up with Syapse to add oncologists to clinical research network
Jan 14, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for N-Power Medicine.
N-Power Medicine partners with MSD to expand access to oncology clinical trials
Jul 2, 2024